Avidity Biosciences (RNA) – Research Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Avidity Biosciences (NASDAQ: RNA) in the last few weeks:

• 9/27/2025 – Avidity Biosciences had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/22/2025 – Avidity Biosciences had its price target lowered by analysts at Evercore ISI from $70.00 to $65.00. They now have an “outperform” rating on the stock.
• 9/17/2025 – Avidity Biosciences is now covered by analysts at Roth Capital. They set a “buy” rating and a $62.00 price target on the stock.
• 9/15/2025 – Avidity Biosciences had its price target raised by analysts at Bank of America Corporation from $56.00 to $65.00. They now have a “buy” rating on the stock.
• 9/12/2025 – Avidity Biosciences had its price target raised by analysts at HC Wainwright from $68.00 to $87.00. They now have a “buy” rating on the stock.
• 9/10/2025 – Avidity Biosciences had its price target raised by analysts at Needham & Company LLC from $60.00 to $65.00. They now have a “buy” rating on the stock.
• 9/10/2025 – Avidity Biosciences had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $75.00 price target on the stock.
• 8/8/2025 – Avidity Biosciences had its price target raised by analysts at Wells Fargo & Company from $70.00 to $75.00. They now have an “overweight” rating on the stock.
• 8/8/2025 – Avidity Biosciences had its “overweight” rating reaffirmed by analysts at Barclays PLC. They now have a $62.00 price target on the stock, up previously from $59.00.
• 8/8/2025 – Avidity Biosciences had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $75.00 price target on the stock.

Insider Activity

In other news, Director Troy Edward Wilson sold 65,554 shares of the stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $45.00, for a total transaction of $2,949,930.00. Following the transaction, the director owned 17,776 shares of the company’s stock, valued at $799,920. This represents a 78.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Steven George Hughes sold 81,434 shares of the business’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $42.74, for a total value of $3,480,489.16. Following the completion of the sale, the insider directly owned 38,867 shares of the company’s stock, valued at $1,661,175.58. The trade was a 67.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 542,707 shares of company stock valued at $24,904,454. Corporate insiders own 3.83% of the company’s stock.

Avidity Biosciences, Inc, a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial.